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Two-year Clinical Outcomes of Patients with Long Segments 
Drug-Eluting Stents: Comparison of Sirolimus-Eluting Stent with 
Paclitaxel-Eluting Stent 
Limited data are available on the long-term clinical efficacy of drug-eluting stent (DES) in 
diffuse long lesions. From May 2006 to May 2007, a total of 335 consecutive patients (374 
lesions) were underwent percutaneous coronary intervention with implantation of long 
DES ( ≥ 30 mm) in real world practice. Eight-month angiographic outcomes and 2-yr 
clinical outcomes were compared between SES (n = 218) and PES (n = 117). Study 
endpoints were major adverse cardiac events including cardiac death, myocardial 
infarction, target-lesion revascularization, target-vessel revascularization and stent 
thrombosis. Baseline characteristics were similar in the two groups as were mean stent 
length (44.9 ± 15.2 mm in SES and 47.4 ± 15.9 in PES, P = 0.121). Late loss at 8 months 
follow-up was significantly lower in SES than in PES group (0.4 ± 0.6 mm in SES vs 
0.7 ± 0.8 mm in PES, P = 0.007). Mean follow-up duration was 849 ± 256 days, and 2-yr 
cumulative major adverse cardiac events were significantly lower in the SES than in the 
PES group (5.5% in SES vs 15.4% in PES, P = 0.003). In conclusion, long-term DES use in 
diffuse long coronary lesions is associated with favorable results, with SES being more 
effective and safer than PES in this real-world clinical experience.
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Cardiovascular Disorders
INTRODUCTION
Although drug-eluting stent (DES) use has remarkably reduced 
in-stent restenosis (ISR) and neointimal hyperplasia, percuta-
neous coronary intervention (PCI) of diffuse long coronary ar-
tery lesions remains challenging (1, 2); these lesions are com-
monly encountered in routine clinical practice and often lead 
to use long stented segments with stent overlap. Because stent-
ed segment length was a known independent predictor of ISR 
in the bare-metal stent (BMS) era and limited data are available 
on the long-term efficacy and safety of DES in diffuse long cor-
onary artery lesions, we investigated the long-term efficacy and 
safety of DES in diffuse long lesions (3-5).
MATERIALS AND METHODS
Study population
From May 2006 to May 2007, a total of 335 consecutive patients 
(374 lesions) underwent PCI with implantation of long DES ( ≥  
30 mm) in de novo long coronary artery lesions at 3 cardiac cen-
ters (Inje University Busan Paik Hospital in Busan, Yeungnam 
University Medical Center in Daegu and Keimyung University 
Dongsan Hospital in Daegu) in Korea. Patients were divided into 
sirolimus-eluting stent (SES, Cypher, Cordis, Johnson & Johnson, 
Roden, The Netherlands, n = 218) and paclitaxel-eluting stent 
(PES, Taxus, Boston Scientific Corp, Natick, MA, USA, n = 117) 
recipient groups, and 8-month angiographic 2-yr clinical out-
comes were compared.
Procedures and medications
All interventions were performed using standard techniques. 
DES selection, Glycoprotein IIb/IIIa inhibitors and intravascu-
lar ultrasound (IVUS) were used at the discretion of the opera-
tor. All patients received a loading dose of 300 mg clopidogrel 
followed by a daily dosage of 75 mg for 12 months, in addition 
to life-long aspirin therapy. Kim U, et al.  •  Outcomes of SES and PES in Long Coronary Artery Lesions
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Follow-up
Angiographic follow-up was recommended for all living patients 
at 8 months after index procedure. Clinical follow-up was per-
formed for all patients at 1, 3, 6, 9 and 12 months, and every 3 
months thereafter either during out-patient department visits 
or by direct telephone calls to patients. 
Study outcomes and definitions
Study outcome was a composite of major adverse cardiac events 
(MACE) including cardiac death, myocardial infarction (MI), 
target-lesion revascularization (TLR), target-vessel revascular-
ization (TVR) and stent thrombosis (ST). 
  Procedural success was defined as residual diameter stenosis 
≤ 30% and the absence of any-in hospital MACE. MI was diag-
nosed when cardiac enzyme (creatine kinase MB fraction) levels 
were elevated more than threefold the normal level, with chest 
pain lasting  ≥ 30 min, or with the appearance of new electrocar-
diographic changes, or with imaging evidence of new regional 
wall motion abnormality or loss of viable myocardium. TLR was 
defined as either surgical or percutaneous reintervention driven 
by significant ( > 50%) luminal diameter narrowing within the 
stent or the 5 mm borders proximal and distal to the stent and 
undertaken in the presence of either anginal symptoms or ob-
jective evidence of ischemia. TVR was defined as revasculariza-
tion within the target vessel encompassing the target lesion. Stent 
thrombosis (ST) was classified by the Academic Research Con-
sortium definition as definite, probable, or possible and as acute 
(0 to 24 hr), subacute ( > 24 hr to 30 days), late ( > 30 days to 1 yr) 
or very late ( > 1 yr). ST was defined as 1) definite: an acute cor-
onary syndrome with angiographic documentation of either ves-
sel occlusion or thrombus within or adjacent to a previously suc-
cessfully stented vessel or autopsy evidence of stent thrombosis, 
2) probable: acute MI in the distribution of the treated vessel or 
unexplained death  < 30 days after the index PCI and 3) possible: 
unexplained death  > 30 days after the index PCI (6, 7). 
  Angiographic restenosis was defined as  ≥ 50% of a diameter 
stenosis. Cumulative rates of event-free survival and MACE were 
analyzed over a two-year follow-up period.
Quantitative coronary angiographic analysis
The percentage of diameter stenosis, minimal lumen diameter, 
lesion length and reference diameter were analyzed with an au-
tomated edge-detection system (CASS II, Pie Medical, Maas-
tricht, The Netherlands) before the procedure, after the proce-
dure, and at follow-up. Lesion morphology was defined accord-
ing to the guidelines of the American College of Cardiology and 
the American Heart Association (8). 
Statistical analysis
Data are expressed as mean ± SD for continuous variables, and 
as frequencies for categorical variables. A two tailed Student’s t 
test was used to assess differences between continuous variables. 
The chi-square (χ2) test was used for comparison of categorical 
variables. Multivariate logistic regression analysis was carried 
out using the baseline clinical and angiographic characteristics 
to identify the independent predictors of MACEs. The following 
variables were tested; pre-lesion length, overlapping, number of 
stents in long lesion, multi-vessel disease and used stent type. 
Major adverse cardiac event-free survival distributions were es-
timated according to the Kaplan-Meier method. The log-rank 
test was used to compare MACE-free survival between two groups. 
Probability values  < 0.05 were considered significant. Data were 
analyzed with SAS 9.1.3. (SAS Institute Inc., Cary, NC, USA).
Ethics statement
This study was reviewed and approved by the institutional review 
board (DCR-10-14) and is in accordance with the Declaration 
of Helsinki. Informed consent was obtained from all patients.
RESULTS
Baseline characteristics of the patients are presented in Table 1 
and there were no significant differences between groups. An-
giographic and procedural data are shown in Table 2; most le-
sions were type C according to the American College of Cardi-
ology and American Heart Association and guidelines (8). Mean 
lesion length (40.4 ± 14.3 mm in SES and 43.6 ± 15.2 mm in PES, 
P = 0.063) and mean stent length (44.9 ± 15.2 mm in SES and 
47.4 ± 15.9 mm in PES, P = 0.121) did not differ significantly be-
tween groups. Post-procedural diameter stenosis was greater in 
the PES than that in SES group (6.1% ± 4.2% in SES vs 7.9% ±  
5.0% in PES, P = 0.001). Angiographic follow-up at 8 months was 
performed in 47.3% and binary restenosis rate was 2.1% in the 
SES and 5.3% in the PES group (P = 0.094). Late loss was signif-
Table 1. Baseline characteristics of the patients
Parameters SES (n = 218) PES (n = 117) P value
Age (yr) 65 ± 10 63 ± 10 0.062
Gender (male) 139 (63.8%)   79 (67.5%) 0.491
Diabetes mellitus   72 (33.0%)   35 (29.9%) 0.560
Hypertension 117 (53.7%)   65 (55.6%) 0.741
Smoking   63 (28.9%)   37 (31.6%) 0.603
Pre-PCI 17 (7.8%) 10 (8.5%) 0.810
Pre-CABG   1 (0.5%)   2 (1.7%) 0.247
Clinical diagnosis
   Stable angina
   Unstable angina
   STEMI
   NSTEMI
   Silent ischemia
 
  78 (35.8%)
  40 (18.3%)
  56 (25.7%)
  43 (19.7%)
  1 (0.5%)
 
  43 (36.8%)
  17 (14.5%)
  40 (34.2%)
  17 (14.5%)
0
0.370
LVEF (%) 54 ± 12 55 ± 11 0.366
SES, sirolimus-eluting stent; PES, paclitaxel-eluting stent; PCI, percutaneous coronary 
intervention; CABG, coronary artery bypass graft; STEMI, ST-segment elevation myo-
cardial infarction; NSTEMI, non-ST-segment elevation myocardial infarction; LVEF, left 
ventricular ejection fraction.Kim U, et al.  •  Outcomes of SES and PES in Long Coronary Artery Lesions
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icantly lower in the SES than in the PES (0.4 ± 0.6 mm in SES vs 
0.7 ± 0.8 mm in PES, P = 0.007, Table 3). Mean clinical follow-up 
duration was 849 ± 256 days. In-hospital MACE rates were not 
statistically different between groups (1.8% in SES vs 2.6% in PES, 
P = 0.656, Table 4). During hospitalization, 4 patients in the SES 
group died; 2 with cardiogenic shock, 1 with cardiogenic shock 
and acute stent thrombosis, and one with cardiac tamponade, 
while two patients in the PES group died of cardiogenic shock 
after acute myocardial infarction (Table 4). At one-month follow-
up, one additional patient died after subacute stent thrombosis 
in the SES group, and likewise in the PES group (Table 4). At one 
year follow-up, two additional deaths occurred in the PES group 
related to late stent thrombosis, while there were no deaths in 
the SES group. At two-year follow-up, two additional deaths were 
found in the PES group related to heart failure; however, there 
were no additional cases of stent thrombosis (Table 4). Cumu-
lative total MACE showed SES yielded superior results than PES 
(5.5% in SES vs 15.4% in PES, P = 0.003). MACE-free survival 
rates are presented in Figs. 1, 2 shows TVR-free survival and Fig. 
3 shows myocardial infarction, death and stent thrombosis free 
survival.
  From test variables with pre-lesion length, overlapping, num-
ber of stents in long lesion, multi-vessel disease and used stent 
type, the independent risk factors of MACE for diffuse long cor-
onary artery lesions were used stent (P = 0.003, odds ratio 3.181, 
C.I. 1.492-6.779) and overlapping stent (P = 0.025, odds ratio 
1.790, C.I. 0.814-3.937). 
Table 2. Angiographic and procedural findings
Procedures or variables SES (n = 241) PES (n = 133) P value
Lesion type*
   B2
   C
 
12 (5.0%)
223 (92.5%)
 
  6 (4.5%)
124 (93.2%)
0.894
Modified lesion type
†
   B2
   C
 
109 (45.2%)
  66 (27.4%)
 
  51 (38.3%)
  42 (31.6%)
0.610
Disease vessel number
   1 vessel
   2 vessels
   3 vessels
 
101 (41.9%)
  66 (27.4%)
  74 (30.7%)
 
  40 (30.1%)
  44 (33.1%)
  49 (36.8%)
0.078
Target artery
   LAD
   LCX
   RCA
 
126 (52.3%)
  28 (11.6%)
  87 (36.1%)
 
  58 (43.6%)
  25 (18.8%)
  50 (37.6%)
0.106
Bifurcation lesion   50 (20.7%)   30 (22.6%) 0.683
Infarct-related artery   87 (36.1%)   51 (38.3%) 0.666
Stent
   Size (mm)
   Length (mm)
 
  3.0 ± 0.2
  44.9 ± 15.2
 
  3.0 ± 0.3
  47.4 ± 15.9
 
0.157
0.121
Maximal pressure (atm) 15.9 ± 2.0 15.8 ± 2.0 0.863
Post-dilatation   45 (18.7%)   34 (25.6%) 0.118
Overlapping stent 112 (46.5%)   74 (55.6%) 0.090
Stent number at target lesion   1.7 ± 0.5   1.8 ± 0.6 0.089
Lesion length (mm)   40.4 ± 14.3   43.6 ± 15.2 0.063
Pre-PCI 
   RD (mm)
   MLD (mm)
   DS (%)
 
  2.8 ± 0.4
  0.3 ± 0.2
88.6 ± 9.1
 
  2.8 ± 0.4
  0.3 ± 0.2
  87.8 ± 10.3
 
0.842
0.491
0.428
Post-PCI
   MLD (mm)
   DS (%)
 
  2.7 ± 0.3
  6.1 ± 4.2
 
  2.7 ± 0.3
  7.9 ± 5.0
 
0.100
0.001
Acute gain   2.4 ± 0.3   2.4 ± 0.4 0.543
*According to the ACC/AHA guidelines (8); 
†Modified lesion classification excluding 
lesion length. SES, sirolimus-eluting stent; PES, paclitaxel-eluting stent; LAD, left an-
terior descending artery; LCX, left circumflex artery; RCA, right coronary artery; PCI, 
percutaneous coronary intervention; RD, reference diameter; MLD, minimal lumen 
diameter; DS, diameter stenosis.
Table 3. Follow-up angiographic results
Parameters SES (n = 241) PES (n = 133) P value
Follow-up CAG 109 (45.2%) 68 (51.1%) 0.274
Restenosis   5 (2.1%) 7 (5.3%) 0.094
Restenosis type
   Body
   Edge
   Diffuse
   Total
  
  1 (0.4%)
  1 (0.4%)
  1 (0.4%)
  2 (0.8%)
  
0
5 (3.8%)
0
2 (1.5%)
0.110
RD (mm) 2.9 ± 0.4 3.0 ± 0.4 0.178
MLD (mm) 2.3 ± 0.7 2.0 ± 0.8 0.034
DS (%) 21.6 ± 21.5 31.4 ± 22.5 0.007
Late loss (mm) 0.4 ± 0.6 0.7 ± 0.8 0.007
SES, sirolimus-eluting stent; PES, paclitaxel-eluting stent; CAG, coronary angiogra-
phy; RD, reference diameter; MLD, minimal lumen diameter; DS, diameter stenosis.
Table 4. Major adverse cardiac events (MACE) at 2 yr
Adverse events SES (n = 218) PES (n = 117) P value
In-hospital MACE
   Myocardial infarction
   TLR/TVR/CABG
   Death
   Stent thrombosis
4 (1.8%)
0
0
4 (1.8%)
0
3 (2.6%)
2 (1.7%)
0
1 (0.9%)
1 (0.9%)
0.656
0.053
 
0.481
0.172
1-month MACE
   Myocardial infarction
   TLR/TVR/CABG
   Death
   Stent thrombosis
2 (0.9%)
2 (0.9%)
0
1 (0.5%)
1 (0.5%)
3 (2.6%)
2 (1.7%)
0
2 (1.7%)
1 (0.9%)
0.236
0.525
 
0.247
0.654
1-yr MACE
   Myocardial infarction
   TLR
   TVR
   CABG
   Death
   Stent thrombosis
4 (1.8%)
0
3 (1.4%)
5 (2.3%)
0
0
0
8 (6.8%)
3 (2.6%)
6 (5.1%)
6 (5.1%)
0
2 (1.7%)
2 (1.7%)
0.019
0.018
0.043
0.165
 
0.053
0.053
2-yr MACE
   Myocardial infarction
   TLR
   TVR
   CABG
   Death
   Stent thrombosis
2 (0.9%)
0
2 (0.9%)
2 (0.9%)
0
0
0
6 (5.1%)
5 (4.3%)
2 (1.7%)
2 (1.7%)
0
2 (1.7%)
0
0.016
0.002
0.525
0.525
 
0.053
 
Cumulative total MACE
   Myocardial infarction
   TLR
   TVR
   CABG
   Death
   Stent thrombosis
12 (5.5%)
4 (1.8%)
5 (2.3%)
6 (2.8%)
0
5 (2.3%)
1 (0.5%)
7 (15.4%)
10 (8.5%)
9 (7.7%)
10 (8.5%)
0
7 (6.0%)
4 (3.4%)
0.003
0.003
0.019
0.018
-
0.165
0.033
SES, sirolimus-eluting stent; PES, paclitaxel-eluting stent; MACE, major adverse car-
diac events; TLR, target-lesion revascularization; TVR, target-vessel revascularization; 
CABG, coronary artery bypass graft.Kim U, et al.  •  Outcomes of SES and PES in Long Coronary Artery Lesions
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DISCUSSION
The major finding of this study is that long-term follow-up of DES 
implantation in diffuse long coronary lesions showed acceptable 
low rates of clinical events, with SES being more effective and 
safer than PES in this real-world clinical experience.
  Restenosis remains a major problem in treating with DES use, 
particularly in off-label usage such as in diffuse long lesions. 
Stent type can affect the risk of restenosis and SES is superior in 
terms of late loss and restenosis (9, 10). 
  Lee et al. (11) reported that the full metal jacket DES method 
was safe and effective in the treatment of diffuse long coronary 
artery disease with restenosis rates of 11.1% and 22.2% for SES 
and PES, respectively, suggesting that the risk of restenosis is in-
fluenced by the type of DES used. Kim et al. (12) also reported 
that for patients with long coronary artery disease, SES implan-
tation was associated with a reduced incidence of angiographic 
restenosis and a reduced need for TLR compared with PES im-
plantation, although incidence of death or myocardial infarction 
at 9-month follow-up was not significantly different. Our study 
yielded similar results with SES use being associated with better 
outcomes than PES use, which might be due to significantly lower 
late loss (0.4 ± 0.6 mm in SES vs 0.7 ± 0.8 mm in PES, P = 0.007) 
and TVR rates (2.8% in SES vs 8.5% in PES, P = 0.018). The out-
come rates in this study were more favorable than those in the 
study by Lee et al. (11), which may be secondary to differences 
in lesion length (mean stent length 71.9 ± 13.7 mm in Lee et al. 
report (11) vs 45.8 ± 15.5 mm in the present study), because ISR 
occurrence increases with increased stented length. However, 
this study was not focused on full lesion coverage such as with 
full metal jackets, but on the treatment of long lesions more com-
monly seen in the real-world clinical practice.
  Our study showed that MACE of patients with SES had better 
results in not only efficacy (TLR/TVR) but also myocardial infarc-
tion and cardiac death. Compared with the previous reports, 
our study represented different results in hard endpoints because 
our data reflected real world clinical practice and long term fol-
low-up for 2 yr in diffuse long coronary artery lesion (13). 
  From our study, small differences already uncovered before 
one year follow-up, however the results came to clearer towards 
two years. This represents short-term follow-up is necessary but 
also long-term follow-up is important in patients treated with 
DES, especially PES, in diffuse long lesions.
  Stent thrombosis is another important complication in pa-
tients treated with DES, especially in diffuse long lesions. One 
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Fig. 1. Cumulative major adverse cardiac event (MACE) free survival is represented. 
Follow-up duration was 849 ± 256 days. The outcomes associated with sirolimus-
eluting stent (SES) use were better than those of paclitaxel-eluting stent (PES) use 
(93% in SES vs 85% in PES, P = 0.013). 
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Fig. 2. Target vessel revascularization-free survival rate is represented. The outcomes 
of sirolimus-eluting stent were better than those of paclitaxel-eluting stent (97% in 
SES vs 91% in PES, P = 0.014).
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Fig. 3. Myocardial infarction, death and stent thrombosis free survival rate is repre-
sented. The outcomes of sirolimus-eluting stent were better than those of paclitaxel-
eluting stent (97% in SES vs 89% in PES, P = 0.002).Kim U, et al.  •  Outcomes of SES and PES in Long Coronary Artery Lesions
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study reported a 9-month late stent thrombosis rate of 1.25% (4/ 
318) for a mean stent length  ≥ 55 mm (14). In the present study, 
4 stent thrombosis (one acute, two sub-acute and one late) events 
developed in the PES group (3.4%), while only one subacute 
stent thrombosis occurred in the SES group (0.5%, P = 0.033). 
The reasons for this significant difference are unknown and 
might include multiple factors such as different environmental 
or individual factors. 
  There are several limitations in this study. First, angiographic 
follow-up was performed only in 47.3% of patients, which might 
underestimate restenosis rates. This could be another major 
source of selection bias. So we compared between the patients 
with and without angiographic follow-up. However, there were 
no differences in baseline characteristics and angiographic, pro-
cedural findings. Second, the total number of patients was rela-
tively small to fully assess the safety and efficacy of DES. Third, 
this study is a retrospective analysis and stent selection was not 
randomized and could be biased. So we used multivariate re-
gression analysis. From this analysis, used stent and overlapping 
proved independent risk factors for MACE in patients with dif-
fuse long coronary artery disease as described early. Fourth, an-
other type DES like zotarolimus-eluting stent and second gen-
eration DES such as everolimus-eluting stent were not included 
in this study and further investigation will be warranted.
  In conclusion, long-term DES use in diffuse long coronary 
lesions is associated with favorable results, with SES being more 
effective and safer than PES in this real-world clinical experience.
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Long-term clinical efficacy and safety of drug-eluting stent (DES) in diffuse long lesions are not well-known. We analyzed 335 
consecutive patients underwent percutaneous coronary intervention with implantation of long DES. Clinical outcomes were 
compared between Sirolimus-eluting stent (SES, n = 218) and Paclitaxel-eluting stent (PES, n = 117). Two-yr cumulative major 
adverse cardiac event was significantly lower in the SES than in the PES group. DES use in diffuse long coronary lesions was 
associated with acceptable low rates of clinical events with SES being more effective and safer than PES.